EULAR 2024 | congress satellite symposia & consult-the-expert
A number of Satellite Symposia and Consult-The-Expert events will be organised during EULAR 2024, 12 June - 15 June. We invite you to explore our Industry Programme e-booklet (PDF) to discover which ones.
Satellite Symposia and Consult-The-Expert are governed by the EULAR Code of Practice, and are strictly prohibited during the official programme hours. All symposia and special events must be approved by EULAR.
SCHEDULE OVERVIEW
WEDNESDAY, 12 JUNE 2024 |
|
| 15:45 - 16:15 | Consult-The-Expert (1 session) |
| 18:30 - 19:45 | Satellite Symposia (8 parallel sessions) |
THURSDAY, 13 JUNE 2024 |
|
| 08:15 - 09:30 | Satellite Symposia (7 parallel sessions) |
| 09:45 - 10:15 | Consult-The-Expert (3 parallel sessions) |
| 15:00 - 15:30 |
Consult-The-Expert (2 parallel sessions) |
| 17:30 - 18:45 | Satellite Symposia (8 parallel sessions) |
FRIDAY, 14 JUNE 2024 |
|
| 08:15 - 09:30 | Satellite Symposia (5 parallel sessions) |
| 09:45 - 10:15 | Consult-The-Expert (3 parallel sessions) |
| 17:30 - 18:45 |
Satellite Symposia (3 parallel sessions) |
Satellite Symposia Programme overview
12 June I 18:30 – 19:45 CEST
AbbVie - The Great Quest for Disease Control in PsA
12 June I 18:30 – 19:45 CEST
Alfasigma - JAK inhibitors in practice: unlocking the potential in the real world of RA
12 June I 18:30 – 19:45 CEST
AstraZeneca - Remission in SLE: paving the way to improved patient care
12 June I 18:30 – 19:45 CEST
GSK - Advancing lupus care: acting early to reduce the risk of organ damage progression
12 June I 18:30 – 19:45 CEST
Johnson & Johnson - Charting the long course of psoriatic arthritis
12 June I 18:30 – 19:45 CEST
Novartis - The Great Scientific Debate: IL-1β Inhibition vs IL-1 Receptor Blockade in AOSD
12 June I 18:30 – 19:45 CEST
Sobi - Crystallising Options: Overcoming Challenges in the Care of Severe Gout
12 June I 18:30 – 19:45 CEST
UCB - A Visit to the RFuture: Maximising Impact by Personalised Treatment in RA
13 June I 08:15 – 09:30 CEST
BMS - What makes deucravacitinib TYK?
13 June I 08:15 – 09:30 CEST
Boehringer Ingelheim - Systemic sclerosis: addressing the challenges
13 June I 08:15 – 09:30 CEST
Eli Lilly - Dispelling common myths in Spondyloarthritis
13 June I 08:15 – 09:30 CEST
GSK - EGPA Care Reimagined: Biologics through the lens of RWE
13 June I 08:15 – 09:30 CEST
Merck - Toll-Like Receptors: an evolving story in lupus
13 June I 08:15 – 09:30 CEST
Novartis - Revealing New Layers: How Targeting IL-17A is Shaping Rheumatic and Musculoskeletal Disease Management
13 June I 08:15 – 09:30 CEST
Pfizer - Expert perspectives: patient selection for tofacitinib in RA
13 June I 17:30 – 18:45 CEST
AbbVie - All Aboard!: Choosing the Right Tracks to Accelerate Patients With RA and SpA Toward Their Goals
13 June I 17:30 – 18:45 CEST
AstraZeneca - The mission for remission: what is now possible for our patients?
13 June I 17:30 – 18:45 CEST
BMS - CAR T therapy - bringing a decade of successful experience to patients with Autoimmune diseases
13 June I 17:30 – 18:45 CEST
Boehringer Ingelheim - Tackling interstitial lung disease in patients with systemic sclerosis or rheumatoid arthritis
13 June I 17:30 – 18:45 CEST
CSL Vifor - Excellence in ANCA-associated vasculitis (AAV) – from diagnosis to optimal care
13 June I 17:30 – 18:45 CEST
Johnson & Johnson - The cycle of inflammation: IL-23 across psoriatic disease
13 June I 17:30 – 18:45 CEST
Pfizer - Expert perspectives: cross-speciality applications of tofacitinib in AS and UC
13 June I 17:30 – 18:45 CEST
UCB - Time to Revolutionise Clinical Practice? Striving for Resolution of Inflammation with the Dual Inhibition of IL-17A and IL-17F in PsA and axSpA
14 June I 08:15 – 09:30 CEST
Cabaletta Bio - Immune Reset: The Potential of CAR T Cell Therapy to Transform the Treatment of Patients with Autoimmune Disease
Session details
14 June I 08:15 – 09:30 CEST
GSK - EGPA: Exploring the emerging evidence
14 June I 08:15 – 09:30 CEST
Kyverna - Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond
14 June I 08:15 – 09:30 CEST
Medac - Optimizing methotrexate – how to achieve maximum results with the anchor drug of RA therapy
14 June I 08:15 – 09:30 CEST
Otsuka - What’s new in Lupus Nephritis: from guidelines to real-world practices
14 June I 17:30 – 18:45 CEST
Amgen - What’s New in IgG4-Related Disease and Where Do We Go Next
14 June I 17:30 – 18:45 CEST
AstraZeneca - Rheumatology meets pulmonology: holistic perspectives for EGPA
14 June I 17:30 – 18:45 CEST
Sanofi - Unveiling the Clinical Canvas: Navigating Unmet Needs in Polymyalgia Rheumatica
Consult-the-expert programme overview
12 June I 15:45 – 16:15 CEST
GSK - New Paths, New Crossroads: Seeing into Systemic Sclerosis
13 June I 09:45 – 10:15 CEST
GSK - Seizing the Window of Opportunity in Lupus: How to Achieve Disease Modification
Session details
13 June I 09:45 – 10:15 CEST
Johnson & Johnson - With a little help from my peers: challenging PsA cases in daily practice
13 June I 09:45 – 10:15 CEST
Sobi - Macrophage Activation Syndrome in Still’s Disease – Current State and Future Horizons of Patient Management
13 June I 15:00 – 15:30 CEST
GSK - Practical considerations when advancing lupus care
13 June I 15:00 – 15:30 CEST
Novartis - FMF: the role of canakinumab in the treatment paradigm
14 June I 09:45 – 10:15 CEST
AstraZeneca - Achieving disease control across organ systems – expert perspectives from the real world
Session details
14 June I 09:45 – 10:15 CEST
UCB - Unlock Your Digital Impact: Social Media Master Class
14 June I 09:45 – 10:15 CEST
GSK - The power of prevention: Why herpes zoster vaccination matters in patients with rheumatic diseases
